PMID- 34103974
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 1178-7074 (Print)
IS  - 1178-7074 (Electronic)
IS  - 1178-7074 (Linking)
VI  - 14
DP  - 2021
TI  - High Levels of Serum IgG for Opisthorchis viverrini and CD44 Expression Predict 
      Worse Prognosis for Cholangiocarcinoma Patients after Curative Resection.
PG  - 2191-2204
LID - 10.2147/IJGM.S306339 [doi]
AB  - BACKGROUND: Opisthorchis viverrini (OV)-associated cholangiocarcinoma (CCA) has a 
      high immune response with chronic inflammation and oxidative stress. CD44 and 
      Nestin, two cancer stem cell (CSC) markers, play major roles in cancer cell 
      survival. Effects of immune response and expression CSC markers on survival of 
      patients with CCA remain unclear. OBJECTIVE: To investigate the effects of level 
      of OV IgG together with CSC marker expression and also the combination of these 
      markers on survival of CCA patients after curative resection. METHODS: All serum 
      specimens from CCA patients who underwent curative surgery from 2005 to 2015 were 
      examined for IgG for OV antigen by ELISA. Tissue specimens were studied for CD44 
      and Nestin expression. Survival analysis by Cox proportional hazard model was 
      used for estimating hazard ratio (HR) with a 95% confidence interval (CI). 
      RESULTS: In this study, 122 (69.3%) of 176 were positive for OV IgG, and 35 
      (19.9%) were considered to have high-positive OV IgG. CD44s positive expression 
      was found in 54 (40%), CD44v6 high expression in 96 (69.6%), CD44v8-10 high 
      expression in 87 (63.5%) and Nestin high expression in 21 (16.1%). Multivariate 
      survival analysis found that high-positive OV IgG and late stage tumor were 
      independent prognostic factors with the adjusted HR of 2.24 (95% CI 1.27-3.93) 
      and 2.78 (95% CI 1.46-5.29), respectively. Subgroup analysis in early and late 
      stage CCA showed that a combined positive OV IgG and CD44s expression with the 
      high expression of CD44v8-10 had the significantly poorest prognosis with HR of 
      3.75 (95% CI 1.61-8.72) and HR of 1.76 (95% CI 1.02-3.03), respectively. 
      CONCLUSION: A high level of OV IgG as well as a high level of CSC markers 
      resulted in an aggressive CCA. OV IgG level together with CSC markers can be used 
      as the prognostic markers for CCA patients' survival. The study of the CD44 
      pathway is promising for adjuvant treatment.
CI  - (c) 2021 Titapun et al.
FAU - Titapun, Attapol
AU  - Titapun A
AUID- ORCID: 0000-0002-2228-752X
AD  - Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Luvira, Vor
AU  - Luvira V
AD  - Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Srisuk, Tharatip
AU  - Srisuk T
AUID- ORCID: 0000-0001-7850-2500
AD  - Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Jareanrat, Apiwat
AU  - Jareanrat A
AD  - Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Thanasukarn, Vasin
AU  - Thanasukarn V
AUID- ORCID: 0000-0002-7976-1915
AD  - Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Thanee, Malinee
AU  - Thanee M
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Sa-Ngiamwibool, Prakasit
AU  - Sa-Ngiamwibool P
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Padthaisong, Sureerat
AU  - Padthaisong S
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Duangkumpha, Kassaporn
AU  - Duangkumpha K
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Suksawat, Manida
AU  - Suksawat M
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Loilome, Watcharin
AU  - Loilome W
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Sithithaworn, Paiboon
AU  - Sithithaworn P
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Techasen, Anchalee
AU  - Techasen A
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, 
      Thailand.
FAU - Thinkhamrop, Bandit
AU  - Thinkhamrop B
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Department of Epidemiology and Biostatistics, Faculty of Public Health, Khon Kaen 
      University, Khon Kaen, Thailand.
FAU - Dzienny, Alexa
AU  - Dzienny A
AD  - School of Medicine and Health Sciences, George Washington University, Washington, 
      DC, USA.
FAU - Caglayan, Ayse
AU  - Caglayan A
AD  - Faculty of Medicine, Imperial College London, London, UK.
FAU - Park, David
AU  - Park D
AUID- ORCID: 0000-0001-6898-3662
AD  - Faculty of Medicine, Imperial College London, London, UK.
FAU - Mahmud, Simran
AU  - Mahmud S
AUID- ORCID: 0000-0003-4125-7489
AD  - Faculty of Medicine, Imperial College London, London, UK.
FAU - Khuntikeo, Narong
AU  - Khuntikeo N
AUID- ORCID: 0000-0001-9305-0688
AD  - Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, 
      Thailand.
AD  - Cholangiocarcinoma Research Institute (CARI), Khon Kaen University, Khon Kaen, 
      Thailand.
LA  - eng
PT  - Journal Article
DEP - 20210601
PL  - New Zealand
TA  - Int J Gen Med
JT  - International journal of general medicine
JID - 101515487
PMC - PMC8179826
OTO - NOTNLM
OT  - CCA
OT  - CD44s
OT  - CD44v8-10
OT  - OV IgG antibody
OT  - OV-associated CCA
OT  - survival
COIS- The authors report no conflicts of interest in this work.
EDAT- 2021/06/10 06:00
MHDA- 2021/06/10 06:01
PMCR- 2021/06/01
CRDT- 2021/06/09 06:41
PHST- 2021/02/14 00:00 [received]
PHST- 2021/04/29 00:00 [accepted]
PHST- 2021/06/09 06:41 [entrez]
PHST- 2021/06/10 06:00 [pubmed]
PHST- 2021/06/10 06:01 [medline]
PHST- 2021/06/01 00:00 [pmc-release]
AID - 306339 [pii]
AID - 10.2147/IJGM.S306339 [doi]
PST - epublish
SO  - Int J Gen Med. 2021 Jun 1;14:2191-2204. doi: 10.2147/IJGM.S306339. eCollection 
      2021.